Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...

Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target on Travere Therapeutics (NASDAQ:TVTX) to $32.00, up from the previous $27.00, while retaining a Sector Outperform rating for the ...

The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...

Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) ...

She was diagnosed with a genetic kidney disease called reflux nephropathy which later progressed to kidney failure. "That was ...

Determined to fight back, Becca will be joining kidney patients and their families from across the region at Kidney Research ...

Travere Therapeutics shares rose sharply in early trading Tuesday after the biopharmaceutical company said it plans to seek expanded Food and Drug Administration approval of its kidney-disease drug ...

Shares of Travere Therapeutics Inc. surged over 13% Tuesday afternoon, reaching their highest level since October 2022 and ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.